Zoster vaccine

Vaccines: Sixth Edition

Volumn , Issue , 2012, Pages 969-980

  Levin, Myron J ^a  

^a University of Colorado Denver and Children s Hospital Colorado   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84902059027     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4557-0090-5.00012-4     Document Type: Chapter

References (200)

1. Levin M.J., Oxman M.N., Zhang J.H., et al. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. J Infect Dis 2008, 197:825-835.
2. Dworkin R.H., Johnson R.W., Breuer J., et al. Recommendations for the management of herpes zoster. J Infect Dis 2007, 44(suppl 1):S1-26.
3. Yawn B.P., Saddier P., Wollan P., et al. A population-based study of the incidence and complication rates of herpes zoster before zoster vaccination. Mayo Clin Proc 2007, 82:1341-1349.
4. Straus S.E., Oxman M.N. Varicella and herpes zoster. Fitzpatick's Dermatology in General Medicine 2008, 2427-2450. McGraw-Hill, New York, NY. I.M. Freedberg, A.Z. Eisen, L. Wolf (Eds.).
5. Oxman M.N., Levin M.J., Johnson G.R., et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005, 352:2271-2284.
6. Schmader K. Herpes zoster in the elderly: issues related to geriatrics. Clin Infect Dis 1999, 28:736-739.
7. Schmader K., Johnson G., Ciarleglio M., et al. Effect of a zoster vaccine on herpes zoster-related interference with functional status and health-related quality of life measures in older adults. J Am Geriatr Soc 2010, 58:1634-1641.
8. Hope-Simpson R.E. The nature of herpes zoster: a long-term study and a new hypothesis. Proc R Soc Med 1965, 58:9-20.
9. Harbecke R., Oxman M.N., Arnold B.A., et al. A real-time PCR assay to identify and discriminate among wild-type and vaccine strains of varicella-zoster virus and herpes simplex virus in clinical specimens. J Med Virol 2009, 81:1310-1322.
10. Harpaz R., Ortega-Sanchez I.R., Seward J.F. Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2008, 57(RR-5):1-30. Advisory Committee on Immunization Practices (ACIP), Centers for Disease Control, Prevention (CDC)Centers for Disease Control, Prevention (CDC).
11. Oxman M.N. Clinical manifestations of herpes zoster. Varicella-Zoster Virus: Virology and Clinical Management 2000, 246-275. Cambridge University Press, Cambridge, England. A.M. Arvin, A.A. Gershon (Eds.).
12. Jako G.J., Jako R.A. Short historical note: connection between varicella and herpes zoster. J Med 1986, 17:267-269.
13. Kundratitz K. Experimentelle übertrangung von herpes zoster auf den mentschen und die beziehungen von herpes zoster zu varicellen. Monatsschrift für kinderheilkunde 1925, 129:516-522.
14. Lipschutz B., Kundratitz K. Über die aetologie des zoster und über seine beziehungen zu varizellen. Wien Wehnschr 1992, 38:499-503.
15. Bruusgaard E. The mutual relation between zoster and varicella. Br J Dermatol 1932, 44:1-24.
16. Garland J. Varicella following exposure to herpes zoster. N Engl J Med 1943, 228:336-337.
17. Weller T.H., Coons A.H. Fluorescent antibody studies with agents of varicella and herpes zoster propagated in vitro. Proc Soc Exp Biol Med 1954, 86:789-794.
18. Weller T.H., Witton H.M., Bell E.J. The etiologic agents of varicella and herpes zoster: isolation, propagation, and cultural characteristics in vitro. J Exp Med 1958, 108:843-868.
19. Straus S.E., Reinhold W., Smith H.A., et al. Endonuclease analysis of viral DNA from varicella and subsequent zoster infections in the same patient. N Engl J Med 1984, 311:1362-1364.
20. Gershon A.A., LaRussa P. Varicella-zoster virus infections. Krugman's Infectious Diseases of Children 2004, 785-816. Mosby, Philadelphia, PA. A.A. Gershon, P.J. Hotez, S.L. Katz (Eds.).
21. Heininger U., Seward J.F. Varicella. Lancet 2007, 368:1365-1376.
22. Kilgore P.E., Kruszon-Moran D., Seward J.F., et al. Varicella in Americans from NHANES III: implications for control through routine immunization. J Med Virol 2003, 70(suppl 1):S111-S118.
23. Ku C.-C., Besser J., Abendroth A., et al. Varicella zoster virus pathogenesis and immunobiology: new concepts emerging from investigations with the SCIDhu mouse model. J Virol 2005, 79:2651-2658.
24. Ku C.-C., Padilla J.A., Grose C.G., et al. Tropism of varicella-zoster virus for human tonsillar CD4+ T lymphocytes that express activation, memory, and skin homing markers. J Virol 2002, 22:11425-11433.
25. Arvin A.M., Moffatt J.F., Sommer M., et al. Varicella-zoster virus T cell tropism and the pathogenesis of skin infection. Varicella-Zoster Virus: Current Topics in Microbiology and Immunology 2010, 189-209. Springer-Verlag, Berlin, Germany. A. Arvin, A. Abendroth (Eds.).
26. Abendroth A., Morrow G., Cunningham A.L., et al. Varicella-zoster virus infection of human dendritic cells and transmission to T cells: Implications for virus dissemination in the host. J Virol 2001, 75:6183-6192.
27. Ozaki T., Kajita Y., Asano Y., et al. Detection of varicella-zoster virus DNA in blood of children with varicella. J Med Virol 1994, 44:263-265.
28. Muraki R., Baba T., Iwasaki T., et al. Immunohistochemical study of skin lesions in herpes zoster. Virchows Arch A Pathol Anat Histopathol 1992, 420:71-76.
29. Gershon A.A., LaRussa P., Steinberg S., et al. The protective effect of immunologic boosting against zoster: an analysis in leukemic children who were vaccinated against chickenpox. J Infect Dis 1996, 173:450-453.
30. Galea S.A., Sweet A., Beninger P., et al. The safety profile of varicella vaccine: a ten year review. J Infect Dis 2007, 197(suppl 2):S165-S169.
31. Gilden D.H., Gesser R., Smith J., et al. Presence of VZV and HSV-1 DNA in human nodose and celiac ganglia. Virus Genes 2001, 23:145-147.
32. Chen J., Gershon A., Bischoff S., et al. Latency of VZV in ganglia of the human small and large intestines [abstract]. Program and abstracts of the 30th Annual International Herpesvirus Workshop (Turku, Finland) 2005, International Herpesvirus Workshop, Abstract 7.19.
33. Mahalingam R., Wellish M., Wolf W., et al. Latent varicella-zoster virus DNA in human trigeminal and thoracic ganglia. N Engl J Med 1990, 323:627-631.
34. Furuta Y., Takasu T., Fukuda S., et al. Detection of varicella-zoster virus DNA in human geniculate ganglia by polymerase chain reaction. J Infect Dis 1992, 166:1157-1159.
35. Eshleman E., Shahzad A., Cohrs R.J. Varicella zoster virus latency. Future Virol. 2011, 6:341-355.
36. Gilden D.H., Kleinschmidt-DeMasters B.K., LaGuardia J.J., et al. Neurologic complications of the reactivation of varicella-zoster virus. N Engl J Med 2000, 342:635-645.
37. Cohrs R.J., Randall J., Smith J., et al. Analysis of individual human trigeminal ganglia for latent herpes simplex virus type 1 and varicella-zoster virus nucleic acids using real-time PCR. J Virol 2000, 74:11464-11471.
38. Nagel M.A., Choe A., Traktinskkiy I., et al. Varicella-zoster virus transcriptome in latently infected human ganglia. J Virol 2011, 85:2276-2287.
39. Levin M.J., Cai G.Y., Manchak M.D., et al. Varicella-zoster virus DNA in cells isolated from human trigeminal ganglia. J Virol 2003, 77:6979-6987.
40. Wang K., Lau T.Y., Morales M., et al. Laser-capture microdissection: refining estimates of the quantity and distribution of latent herpes simplex virus 1 and varicella zoster virus DNA in human trigeminal ganglia at the single-cell level. J Virol 2005, 79:14079-14087.
41. Clarke P., Beer T., Cohrs R., et al. Configuration of latent varicella-zoster virus DNA. J Virol 1995, 69:8151-8154.
42. Gowrishankar K., Slobedman B., Cunningham A.L., et al. Productive varicella-zoster virus infection of cultured intact human ganglia. J Virol 2007, 81:6752-6756.
43. Mitchell B.M., Bloom D.C., Cohrs R.J., et al. Herpes simplex virus-1 and varicella-zoster virus in ganglia. J Neurovirol 2003, 9:194-204.
44. Cohrs R.J., Gilden D.H., Kinchington R.R., et al. Varicella-zoster virus gene 66 transcription and translation in latently infected human ganglia. J Virol 2003, 77:6660-6665.
45. Cohrs R.J., Barbour M., Gilden D.H. Varicella-zoster virus (VZV) transcription during latency in human ganglia: detection of transcripts mapping to genes 21, 29, 62, and 63 in a cDNA library enriched for VZV RNA. J Virol 1996, 70:2789-2796.
46. Azarkh Y., Gilden D., Cohrs R.J. Molecular characterization of varicella zoster virus in latently infected human ganglia: physical state and abundance of VZV DNA, quantitation of viral transcripts and detection of VZV-specific proteins. Curr Top Microbiol Immunol 2010, 342:229-241.
47. Cohen J.I. VZV: molecular basis of persistence (latency and reactivation). Human Herpesviruses; Biology, Therapy, and Immunoprophylaxis 2007, 689-699. Cambridge University Press, Cambridge, England. A. Arvin, G. Campadelli-Fiume, E. Mocarski (Eds.).
48. Weinberg A., Levin M.J. VZV T cell-mediated immunity. Curr Top Microbiol Immunol 2010, 342:341-358.
49. Hambleton S., Gershon A.A. Preventing varicella-zoster disease. Clin Microbiol Rev 2005, 18:70-80.
50. Dolin R., Reichman R.C., Mazur M.H., et al. NIH conference: herpes zoster-varicella infections in immunosuppressed patients. Ann Intern Med 1978, 89:375-388.
51. Buchbinder S.P., Katz M.H., Hessol N.A., et al. Herpes zoster and human immunodeficiency virus infection. J Infect Dis 1992, 166:1153-1156.
52. Wilson A., Sharp M., Koropchak C.M., et al. Subclinical varicella-zoster virus viremia, herpes zoster, and T lymphocyte immunity to varicella-zoster viral antigens after bone marrow transplantation. J Infect Dis 1991, 165:119-126.
53. Gnann J.W. Herpes simplex and varicella-zoster virus infection after hematopoietic stem cell or solid organ transplantation. Transplant Infections 2010, 391-410. Lippincott Williams & Wilkins, Philadelphia, PA. 3rd ed. R. Bowden, P. Ljungman, D. Snydman (Eds.).
54. Arvin A.M., Pollard R.B., Rasmussen L.E., et al. Cellular and humoral immunity in the pathogenesis of recurrent herpes viral infections in patients with lymphoma. J Clin Invest 1980, 65:869-878.
55. Oxman M.N. Zoster vaccine: current status and future prospects. Clin Infect Dis 2010, 51:197-213.
56. Good R.A., Zak S.J. Disturbances in gamma globulin synthesis as experiments of nature. Pediatrics 1956, 18:109-146.
57. Rosen F.S., Janeway C.A. The gamma globulins, III: the antibody deficiency syndromes. N Engl J Med 1966, 275:709-715.
58. Webster A., Grint P., Brenner M.K., et al. Titration of IgG antibodies against varicella zoster virus before bone marrow transplantation is not predictive of future zoster. J Med Virol 1989, 27:117-119.
59. Steer C.B., Szer J., Sasadeusz J., et al. Varicella-zoster infection after allogeneic bone marrow transplantation: incidence, risk factors and prevention with low-dose acyclovir and ganciclovir. Bone Marrow Transplant 2000, 25:657-664.
60. Redman R.L., Nader S., Zerboni L., et al. Early reconstitution of immunity and decreased severity of herpes zoster in bone marrow transplant recipients immunized with an inactivated varicella vaccine. J Infect Dis 1997, 176:578-585.
61. Hata A., Asunuma H., Rinki M., et al. Use of an inactivated varicella vaccine in recipients of hematopoietic-cell transplants. N Engl J Med 2002, 347:26-34.
62. Ljungman P., Lonnqvist B., Gahrton G., et al. Clinical and subclinical reactivations of varicella zoster virus in immunocompromised patients. J Infect Dis 1986, 153:840-847.
63. Luby J.P., Ramirez-Ronda C., Renner S., et al. A longitudinal study of varicella-zoster infections in renal transplant recipients. J Infect Dis 1977, 135:659-663.
64. Quinlivan M.L., Ayres K., Ran H., et al. Effect of viral load on the outcome of herpes zoster. J Clin Virol 2007, 45:3909-3914.
65. Thomas S.L., Wheeler J.G., Hall A.J. Contacts with varicella or with children and protection against herpes zoster in adults: a case-control study. Lancet 2002, 360:678-682.
66. Amanna I.J., Carlson N.E., Slifka M.K. Duration of humoral immunity to common viral and vaccine antigens. N Engl J Med 2007, 357:1903-1915.
67. Arvin A.M., Koropchak C.M., Wittek A.E. Immunologic evidence of reinfection with varicella-zoster virus. J Infect Dis 1983, 148:200-205.
68. Vossen M.TM., Gent M.-R., Weel J.FL., et al. Development of virus-specific CD4+ T cells on reexposure to varicella-zoster virus. J Infect Dis 2004, 190:72-82.
69. Patterson-Bartlett J., Levin M.J., Lang N., et al. Phenotypic and functional characterization of ex-vivo T cell responses to the live attenuated herpes zoster vaccine. Vaccine 2007, 25:7087-7093.
70. Head H., Campbell A. The pathology of herpes zoster and its bearing on sensory localization. Brain 1900, 23:353-523.
71. Denny-Brown D., Adam R., Fitzgerald P. Pathologic features of herpes zoster: a note on geniculate herpes. Arch Neurol Psychiatry 1944, 51:216-231.
72. Schmidbauer M., Budka H., Pilz P., et al. Presence, distribution and spread of productive varicella zoster virus infection in nervous tissues. Brain 1980, 115:383-398.
73. Watson C.P., Deck J.H., Morshead C., et al. Post-herpetic neuralgia: further post-mortem studies of cases with and without pain. Pain 1991, 44:105-117.
74. Steain M., Gowrishankar K., Rodriguez M., et al. Upregulation of CXCL10 in human dorsal root ganglia during experimental and natural varicella-zoster virus infection. J Virol 2011, 85:626-631.
75. Gowrishankar K., Steain M., Cunningham A.L., et al. Characterization of the host immune response in human ganglia after herpes zoster. J Virol 2010, 84:8861-8870.
76. Miller A.E. Selective decline in cellular immune response to varicella-zoster in the elderly. Neurology 1992, 30:582-587.
77. Berger R., Florent G., Just M. Decrease of the lymphoproliferative response to varicella-zoster virus antigen in the aged. Infect Immun 1981, 32:24-27.
78. Burke B.L., Steele R.W., Beard O.W., et al. Immune response to varicella-zoster in the aged. Arch Intern Med 1982, 142:291-293.
79. Levin M.J., Oxman M.N., Zhang J.H., et al. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. J Infect Dis 2008, 197:825-835.
80. Weinberg A., Lazar A.A., Zerbe G., et al. Influence of age and nature of primary infection on varicella-zoster virus-specific cell-mediated immune responses. J Infect Dis 2010, 201:1024-1030.
81. Irwin M.R., Olmstead R., Oxman M.N. Augmenting immune responses to varicella zoster virus in older adults: a randomized, controlled trial of tai chi. J Am Geriatr Soc 2007, 55:511-517.
82. Schmader K.E., Studenski S., MacMillan J., et al. Are stressful life events risk factors for herpes zoster?. J Am Geriatr Soc 1990, 38:1188-1195.
83. Grose C., Bonthius D., Afifi A.K. Chickenpox and the geniculate ganglion: facial nerve palsy, Ramsay Hunt syndrome and acyclovir treatment. Pediatr Infect Dis J 2002, 21:615-617.
84. Levin M.J., Rinaldo C.R., Leary P.L., et al. The immune response to herpesvirus antigens by adults with acute cytomegalovirus mononucleosis. J Infect Dis 1979, 140:851-857.
85. Thomas S.L., Wheeler J.G., Hall A.J. Case-control study of the effect of mechanical trauma on the risk of herpes zoster. BMJ 2004, 328:439-441.
86. Petursson G., Helgason S., Gudmundsson S., et al. Herpes zoster in children and adolescents. Pediatr Infect Dis J 1998, 17:905-908.
87. Feder H., Hoss D.M. Herpes zoster in otherwise healthy children. Pediatr Infect Dis J 2004, 23:451-460.
88. Schmader K.E., George L.K., Burchett B.M., et al. Race and stress in the incidence of herpes zoster in the elderly. J Am Geriatr Soc 1998, 46:973-977.
89. Hicks L.D., Cook-Norris R.H., Mendoza N., et al. Family history as a risk factor for herpes zoster: a case control study. Arch Dermatol 2008, 144:603-608.
90. Gatti A.P., Boccia M.T., De Antoni F., et al. No evidence of family history as a risk factor for herpes zoster in patients with postherpetic neuralgia. J Med Virol 2010, 82:1007-1011.
91. Gnann J.W., Whitley R.J. Herpes zoster. N Engl J Med 2002, 347:340-346.
92. Dworkin R.H., Johnson R.W., Breuer J., et al. Recommendations for the management of herpes zoster. J Infect Dis 2007, 44(suppl 1):S1-26.
93. Benbernou A., Drolet M., Levin M.J., et al. Association between prodromal pain and the severity of acute herpes zoster and utilization of health care resources. Eur J Pain 2011, 15:1100-1106.
94. Oaklander A.L., Bowsher D., Galer B., et al. Herpes zoster itch: preliminary epidemiological data. J Pain 2003, 4:338-343.
95. Insigna R.P., Itzler R.F., Pellissier J.M. Acute/subacute herpes zoster: healthcare resource utilisation and costs in a group of US health plans. Pharmacoeconomics 2007, 25:155-169.
96. Yawn B.P., Saddier P., Wollan P., et al. A population-based study of the incidence and complication rates of herpes zoster before zoster vaccination. Mayo Clin Proc 2007, 82:1341-1349.
97. Straus S.E., Oxman M.N. Varicella and herpes zoster. Fitzpatick's Dermatology in General Medicine 2008, 2427-2450. McGraw-Hill, New York, NY. I.M. Freedberg, A.Z. Eisen, L. Wolf (Eds.).
98. McKendrick M.W., Ogan P., Care C.C. A 9 year follow up of post herpetic neuralgia and predisposing factors in elderly patients following herpes zoster. J Infect 2009, 59:416-420.
99. Opstelten W., McElhaney J., Weinberger B., et al. The impact of varicella zoster virus: chronic pain. J Clin Virol 2010, 48(suppl 1):S8-S13.
100. Mainka C., Futz B., Geiger H., et al. Characterization of viremia at different stages of varicella-zoster virus infection. J Med Virol 1998, 56:91-98.
101. de Jong M.D., Weel J.FL., Schuurman T., et al. Quantitation of varicella-zoster virus DNA in whole blood, plasma, and serum by PCR and electrochemiluminescence. J Clin Microbiol 2000, 38:2568-2573.
102. Gnann J.W., Whitley R.J. Natural history and treatment of varicella-zoster virus in high-risk populations. J Hosp Infect 1991, 18(suppl A):317-329.
103. McNulty A., Li Y., Radtke U., et al. Herpes zoster and the stage and prognosis of HIV-1 infection. Genitourin Med 1997, 73:467-470.
104. Gilson I.H., Barnett J.H., Conant M.A., et al. Disseminated ecthymatous herpes varicella-zoster virus infection in patients with acquired immunodeficiency syndrome. J Am Acad Dermatol 1989, 20:37-42.
105. Haanpää M., Häkkinen V., Nurmikko T. Motor involvement in acute herpes zoster Muscle Nerve 1997, 20:1433-1438.
106. Haanpää M., Dustidar P., Weinberg A., et al. CSF and MRI findings in patients with acute herpes zoster. Neurology 1998, 51:1405-1411.
107. Cheatham W.J. The relation of heretofore unreported lesions to pathogenesis of herpes zoster. Am J Pathol 1953, 29:401-411.
108. Mazur M.H., Dolin R. Herpes zoster at the NIH: a 20 year experience. Am J Med 1978, 65:738-744.
109. Gilden D.H., Beinlich B.R., Rubinstein E.M., et al. Varicella-zoster virus myelitis: an expanding spectrum. Neurology 1994, 44:1818-1823.
110. Gilden D.S., Cohrs R.J., Mahalingam R., et al. Neurological diseases produced by varicella zoster virus reactivation without rash. Varicella-Zoster Virus: Curr Top Microbiol Immunol 2010, Vol. 342:243-254.
111. Liesegang T.J. Varicella-zoster eye disease. Cornea 1999, 18:511-531.
112. Pavan-Langston D. Viral disease of the ocular anterior segment: basic science and clinical disease. The Cornea 2005, 297-397. Lippincott Williams & Wilkins, Philadelphia, PA. 4th ed. S. Foster, D. Azar, C. Dohlman (Eds.).
113. Johnson R.W., Bouhassira D., Dassianos G., et al. The impact of herpes zoster and post-herpetic neuralgia on quality-of-life. BMC Med 2010, 8:37-50. 10.1186/1741-7015-8-37.
114. Kost R.G., Straus S.E. Postherpetic neuralgia: pathogenesis, treatment, and prevention. N Engl J Med 1996, 335:32-41.
115. Whitley R.J., Volpi A., McKendrick M., et al. Management of herpes zoster and post-herpetic neuralgia now and in the future. J Clin Virol 2010, 48(suppl 1):S20-S28.
116. Oxman M.N., Levin M.J., Johnson G.R., et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005, 352:2271-2284.
117. Bennett G.J. Neuropathic pain: new insights, new interventions. Hosp Pract (Minneap) 1998, 33:95-98. 101-104, 107-110.
118. Schmader K. Herpes zoster in the elderly: issues related to geriatrics. Clin Infect Dis 1999, 28:736-739.
119. Katz J., Cooper E.M., Walther R.R., et al. Acute pain in herpes zoster and its impact on health-related quality of life. Clin Infect Dis 2004, 39:342-348.
120. Schmader K., Johnson G., Ciarleglio M., et al. Effect of a zoster vaccine on herpes zoster-related interference with functional status and health-related quality of life measures in older adults. J Am Geriatr Soc 2010, 58:1634-1641.
121. Loparev V.N., Rubtcova E., Seward J.F., et al. DNA sequence variability in isolates recovered from patients with postvaccination rash or herpes zoster caused by Oka varicella vaccine. J Infect Dis 2007, 195:502-510.
122. Hambleton S., Shapiro G., LaRussa P., et al. Risk of herpes zoster in adults immunized with varicella vaccine. J Infect Dis 2008, 197(suppl 2):S196-S199.
123. Black S., Shinefield H., Ray P., et al. Postmarketing evaluation of the safety and effectiveness of varicella vaccine. Pediatr Infect Dis J 1999, 18:1041-1046.
124. Civen R.H., Chaves S.S., Jumaan A., et al. The incidence and clinical characteristics of herpes zoster among children and adolescents after implementation of varicella vaccination. Pediatr Infect Dis J 2009, 28:954-959.
125. Hope-Simpson R.E. The nature of herpes zoster: a long-term study and a new hypothesis. Proc R Soc Med 1965, 58:9-20.
126. Ragozzino M.W., Melton L.J., Kurland L.T., et al. Population-based study of herpes zoster and its sequelae. Medicine 1982, 61:310-316.
127. Donahue J.G., Choo P.W., Manson J., et al. The incidence of herpes zoster. Arch Intern Med 1995, 155:1605-1609.
128. Yawn B.P., Wollan P.C., Kurland M.J., et al. Herpes zoster recurrences more frequent than previously reported. Mayo Clin Proc 2011, 86:88-93.
129. Galil K., Choo P.W., Donahue J.G., et al. The sequelae of herpes zoster. Arch Intern Med 1997, 157:1209-1213.
130. Drolet M., Brisson M., Schmader K., et al. Predictors of postherpetic neuralgia among patients with herpes zoster: a prospective study. J Pain 2010, 11:1211-1221.
131. Weinberg A., Zhang J.H., Johnson G.R., et al. VZV-specific immune responses after herpes zoster in elderly participants in a trial of a clinically effective herpes zoster vaccine. J Infect Dis 2009, 200:1068-1077.
132. Pellissier J.M., Brisson M., Levin M.J. Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Vaccine 2007, 25:8326-8337.
133. Wood M.J., Kay R., Dworkin R.H., et al. Oral acyclovir therapy accelerates pain resolution in patients with herpes zoster: a meta-analysis of placebo-controlled trials. Clin Infect Dis 1996, 22:341-347.
134. Jackson J.L., Gibbons R., Meyer G., et al. The effect of treating herpes zoster with oral acyclovir in preventing postherpetic neuralgia: a meta-analysis. Arch Intern Med 1997, 157:909-912.
135. Crooks R.J., Jones D.A., Fiddian A.P. Zoster-associated chronic pain: an overview of clinical trials with acyclovir. Scand J Infect Dis Suppl 1991, 78:62-68.
136. Tyring S., Barbarash R.A., Nahlik J.E., et al. Famciclovir for the treatment of acute herpes zoster: effects on acute disease and postherpetic neuralgia: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995, 123:89-96.
137. Beutner K.R., Friedman D.J., Forszpaniak C., et al. Valaciclovir compared with acyclovir for improved therapy of herpes zoster in immunocompetent adults. Antimicrob Agents Chemother 1995, 39:1546-1553.
138. Dworkin R.H., Barbano R.L., Tyring S.K., et al. A randomized, placebo-controlled trial of oxycodone and of gabapentin for acute pain in herpes zoster. Pain 2009, 142:209-217.
139. Raja S.N., Haythornthwaite J.A., Pappagallo M., et al. Opioids versus antidepressants in postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology 2002, 59:1015-1021.
140. Wu C.L., Raja S.N. An update on the treatment of postherpetic neuralgia. J Pain 2008, 9(suppl 1):S19-S30.
141. Whitley R.J., Weiss H., Gnann J.W., et al. Acyclovir with and without prednisone for the treatment of herpes zoster: a randomized, placebo-controlled trial. Ann Intern Med 1996, 125:376-383.
142. Wood M.J., Johnson R.W., McKendrick M.W., et al. A randomized trial of acyclovir for 7 days or 21 days with and without prednisolone for treatment of acute herpes zoster. N Engl J Med 1994, 330:896-900.
143. Berry J.D., Petersen K.L. A single dose of gabapentin reduces acute pain and allodynia in patients with herpes zoster. Neurology 2005, 65:444-447.
144. Dworkin R.H., O'Connor A.B., Audette J., et al. Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clin Proc 2010, 85(suppl):S3-S14.
145. Watson C.PN., Babul N. Efficacy of oxycodone in neuropathic pain: a randomized trial in postherpetic neuralgia. Neurology 1998, 50:1837-1841.
146. Dworkin R.H., Corbin A.E., Young J.P., et al. Pregabalin for the treatment of postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology 2003, 60:1274-1283.
147. Collins S.L., Moore R.A., McQuay H.J., et al. Antidepressants and anticonvulsants for diabetic neuropathy and postherpetic neuralgia: a quantitative systematic review. J Pain Symptom Manage 2000, 20:449-458.
148. Galer B.S., Rowbotham M.C., Perander J., et al. Topical lidocaine patch relieves postherpetic neuralgia more effectively than a vehicle topical patch: results of an enriched enrollment study. Pain 1999, 80:533-538.
149. Backonja M., Wallace M.S., Blonsky E.R., et al. NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia: a randomised, double-blind study. Lancet Neurol 2008, 7:1106-1112.
150. Levin M.J., Murray M., Zerbe G.O., et al. Immune responses of elderly persons 4 years after receiving a live attenuated varicella vaccine. J Infect Dis 1994, 170:522-526.
151. Takahashi M., Okado S., Miyagawa H., et al. Enhancement of immunity against VZV by giving live varicella vaccine to the elderly assessed by VZV skin test and IAHA, gpELISA antibody assay. Vaccine 2003, 21:3845-3853.
152. Levin M.J. Use of varicella vaccines to prevent herpes zoster in older individuals. Arch Virol Suppl 2000, 17:1-9.
153. Trannoy E., Berger R., Holländer G., et al. Vaccination of immunocompetent elderly subjects with a live attenuated Oka strain of varicella zoster virus: a randomized, controlled, dose-response trial. Vaccine 2000, 18:1700-1706.
154. Levin M.J., Murray M., Rotbart H.A., et al. The immune response of elderly individuals to a live attenuated varicella vaccine. J Infect Dis 1992, 166:253-259.
155. Levin M.J., LaFleur B., Goldblatt E., et al. Use of a live attenuated varicella vaccine to boost varicella-specific immune responses in seropositive people 55 years of age and older: duration of booster effect. J Infect Dis 1998, 178(suppl 1):S109-S112.
156. Hayward A.R., Buda K., Jones M., et al. Varicella zoster virus-specific cytotoxicity following secondary immunization with live or killed vaccine. Viral Immunol 1996, 9:241-245.
157. Hayward A.R., Buda K., Levin M.J. Immune response to secondary immunization with live or inactivated VZV vaccine in elderly adults. Viral Immunol 1994, 7:31-36.
158. Coplan P.M., Schmader K., Nikos A., et al. Development of a measure of the burden of pain due to herpes zoster and postherpetic neuralgia for prevention trials: adaptation of the brief pain inventory. J Pain 2004, 5:344-356.
159. Smith J.G., Liu X., Kaufhold R.M., et al. Development and validation of a gamma interferon ELISPOT assay for quantitation of cellular immune responses to varicella-zoster virus. Clin Diagn Lab Immunol 2001, 8:871-879.
160. Levin M.J., Oxman M.N., Bobrove A.M., et al. Dose-ranging safety and immunogenicity study of live attenuated varicella-zoster virus vaccine (Oka/Merck) administered to adults 60 years of age or older 2005, San Antonio, TX.
161. Schmader K., Bobrove A., Levin M., et al. Immunogenicity & safety of varicella-zoster virus (VZV) vaccine administered to older adults with or without diabetes mellitus (DM) or chronic obstructive pulmonary disease (COPD) 2006, Chicago, IL.
162. Merck & Co Zostavax (Zoster Vaccine Live) [package insert]., Accessed January 10, 2011. http://www.merck.com/product/usa/pi_circulars/z/zostavax/zostavax_pi.pdf.
163. Gomi Y., Sunamachi Y., Mori K., et al. Comparison of the complete DNA sequences of the Oka varicella vaccine and its parental virus. J Virol 2002, 76:11447-11459.
164. Schmid D.S. Varicella-zoster virus vaccine: molecular genetics. Curr Top Microbiol Immunol 2010, 342:323-340.
165. Gilderman L.I., Lawless J.F., Nolen T.M., et al. A double-blind, randomized, controlled, multicenter safety and immunogenicity study of a refrigerator-stable formulation of ZOSTAVAX. Clin Vaccine Immunol 2008, 15:314-319.
166. Schlienger K., Lange J., Tyring S.K., et al. T-cellImmunogenicity, kinetics of VZV-specific CD4 γ-IFN production and safety of a live attenuated Oka/Merck zoster vaccine in healthy adults ≥ 60 years of age 2006, Abstract 857., Toronto, Canada.
167. Schmader K., Oxman M.N., Levin M.J., et al. Persistence of zoster vaccine efficacy 2008, Alexandria, VA.
168. Harbecke R., Oxman M.N., Arnold B.A., et al. A real-time PCR assay to identify and discriminate among wild-type and vaccine strains of varicella-zoster virus and herpes simplex virus in clinical specimens. J Med Virol 2009, 81:1310-1322.
169. Tseng H.F., Smith N., Harpaz R., et al. Herpes zoster vaccine in older adults and the risk of subsequent herpes zoster disease. JAMA 2011, 305:160-166.
170. Shapiro E.D., Berg A.T., Austrian R., et al. The protective effect of polyvalent pneumococcal polysaccharide vaccine. N Engl J Med 1991, 325:1453-1460.
171. Schmader KE, Levin MJ, Gnann JW, et al. Efficacy, safety, and tolerability of herpes zoster vaccine in persons 50-59 years of age. Vaccine, in press.
172. Simberkoff M.S., Arbeit R.D., Johnson G.R., et al. Safety of zoster vaccine in the shingles prevention study: a randomized trial. Ann Intern Med 2010, 152:545-554.
173. Tseng H.F. Safety of zoster vaccine in adults: a vaccine safety datalink study Accessed June 6, 2011. http://www.cdc.gov/vaccines/recs/acip/downloads/mtg-slides-feb11/07-4-hz-results-phase.pdf.
174. White R.R., Lenhart G., Singhal P.K., et al. Incremental 1-year medical resource utilization and costs for patients with herpes zoster from a set of US health plans. Pharmacoeconomics 2009, 27:781-792.
175. Singhal P.K., Makin C., Pellissier J., et al. Work and productivity loss related to herpes zoster. J Med Econ. 2011, 14:639-645.
176. Harpaz R., Ortega-Sanchez I.R., Seward J.F. Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2008, 57(RR-5):1-30. Advisory Committee on Immunization Practices (ACIP), Centers for Disease Control and Prevention (CDC)Centers for Disease Control and Prevention (CDC).
177. Mills R., Tyring S.K., Levin M.J., et al. Safety, tolerability, and immunogenicity of zoster vaccine in subjects with a history of herpes zoster. Vaccine 2010, 28:4204-4209.
178. Centers for Disease Control and Prevention General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm Rep 2002, 51(RR-14):1-46.
179. Kerzner B., Murray A.V., Cheng E., et al. Safety and immunogenicity profile of the concomitant administration of ZOSTAVAX and inactivated influenza vaccine in adults aged 50 and older. J Am Geriatr Soc 2007, 55:1499-1507.
180. MacIntyre C.R., McCaughley M., Parrino J., et al. Concomitant administration of zoster and pneumococcal vaccines in adults ≥ 60 years old. Hum Vaccin 2010, 6:894-902.
181. Schmader K.E., Sloane R., Pieper C., et al. The impact of acute herpes zoster pain and discomfort on functional status and quality of life in older adults. Clin J Pain 2007, 23:490-496.
182. Drolet M., Brisson M., Schmader K.E., et al. The impact of herpes zoster and postherpetic neuralgia on health-related quality of life: a prospective study. CMAJ 2010, 182:1731-1736.
183. Oster G., Harding G., Dukes E., et al. Pain, medication use, and health-related quality of life in older persons with postherpetic neuralgia: results from a population-based survey. J Pain 2005, 6:356-363.
184. O'Connor A.B. Neuropathic pain: a review of the quality of life impact, costs, and cost-effectiveness of therapy. Pharmacoeconomics 2009, 27:95-112.
185. Lydick E. Impact of acute herpes zoster on quality of life relative to other diseases. Qual Life Res 1998, 4:41-45.
186. Homberger J., Robertus K. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Ann Intern Med 2006, 145:317-325.
187. Rothberg M.B., Virapongse A., Smith K.J. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Clin Infect Dis 2007, 44:1280-1288.
188. Ortega I. Projected cost-effectiveness of vaccinating US elderly to prevent shingles June 24, 2006, Atlanta, GA.
189. Brisson M., Pellissier J.M., Camden S., et al. The potential cost-effectiveness of vaccination against herpes zoster and post-herpetic neuralgia. Hum Vaccin 2008, 4:238-245.
190. van Hoek A.J., Gay N., Melegara A., et al. Estimating the cost-effectiveness of vaccination against herpes zoster in England and Wales. Vaccine 2009, 27:1454-1467.
191. Andrews R., Heller R.F. The number needed to vaccinate (NNV) and population extensions of the NNV: comparison of influenza and pneumococcal vaccine programs for people aged 65 years and over. Vaccine 2004, 22:2192-2198.
192. Hurley L.P., Lindley M.C., Harpaz R., et al. Barriers to the use of herpes zoster vaccine. Ann Intern Med 2010, 152:555-561.
193. Brisson M., Gay N.J., Edmunds W.J., et al. Exposure to varicella boosts immunity to herpes zoster: implications for mass vaccination against chickenpox. Vaccine 2002, 20:2500-2507.
194. Donahue J., Kieke B., Gargiullo P., et al. Herpes zoster is not associated with past exposures to varicella or children October 12-15, 2006, Toronto, Canada, Abstract LB-29.
195. Jumaan A.O., Yu O., Jackson L.A., et al. Incidence of herpes zoster, before and after varicella-vaccination associated decreases in the incidence of varicella, 1992-2002. J Infect Dis 2005, 191:2002-2007.
196. Law B.J., Chateau D., Walld R., et al. Temporal trends in the annual population-based incidence of herpes zoster by age and gender: Manitoba, 1979-1998. Can J Infect Dis Med Microbiol 2004, 15:357-358.
197. Russell M.L., Schopflocher D.P., Svenson L., et al. Secular trends in the epidemiology of shingles in Alberta. Epidemiol Infect 2007, 135:908-913.
198. Zamora I., Simon J.M., DaSilva M.E., et al. Attenuated varicella virus vaccine in children with renal transplants. Pediatr Nephrol 1994, 8:190-192.
199. Macaladad N., Marcano T., Guzman M., et al. Safety and immunogenicity of a zoster vaccine in varicella-zoster virus seronegative and low-seropositive healthy adults. Vaccine 2006, 25:2139-2144.
200. Tyring S.K., Diaz-Mitoma F., Padget L.G., et al. Safety and tolerability of a high-potency zoster vaccine in adults ≥ 50 years of age. Vaccine 2007, 25:1877-1883.